Skip to main content
C
CorpDigest
Search

Pfizer Inc.

Pharmaceuticals & BiotechnologyFounded 1849
Reviewed by Swet Parvadiya
Company data updated: October 2026

Acquisitions

Pfizer Acquisitions

6

Major Deals Covered

$303.0B

Disclosed Deal Value

What are Pfizer's biggest acquisitions?

Pfizer's largest disclosed acquisition here is Warner-Lambert Company for $111B in 2000. This page covers 6 major deals from 2000 to 2025, each with its price where disclosed and the reason behind it.

Major deals covered
6
Largest deal
Warner-Lambert Company ($111B)
First deal
2000
Most recent
2025
CompanyYearPricePurpose
Warner-Lambert Company2000$111.0BPfizer pursued Warner-Lambert to acquire the Lipitor (atorvastatin) cholesterol-lowering statin franchise which was already on track to become the best-selling drug in history at the time of the acquisition. The deal was structured as a hostile takeover after Warner-Lambert had announced a competing merger agreement with American Home Products (later Wyeth), and Pfizer outbid with a $111 billion all-stock offer. The acquisition also brought significant consumer healthcare brands including Listerine, Benadryl, and Halls.
Pharmacia Corporation2003$60.0BPfizer acquired Pharmacia Corporation for approximately $60 billion in 2003 to add the Celebrex (celecoxib) COX-2 inhibitor franchise, the cancer drug Camptosar, ophthalmology products, and a substantial pipeline. The acquisition was also motivated by post-Lipitor diversification concerns and the need to add research capabilities and marketed products to offset anticipated future patent expirations across the combined portfolio.
Wyeth2009$68.0BPfizer acquired Wyeth for $68 billion during the financial crisis of 2009, using the depressed asset valuations of the period to complete what was then one of the largest pharmaceutical acquisitions in history. The primary strategic targets were the Prevnar pneumococcal vaccine franchise, the Enbrel (etanercept) biologics franchise for rheumatoid arthritis and other inflammatory conditions, the Effexor and Pristiq antidepressants, and Wyeth's substantial consumer healthcare business.
Medivation Inc.2016$14.0BPfizer acquired Medivation for $14 billion in 2016 to secure Xtandi (enzalutamide), an androgen receptor inhibitor for prostate cancer that was among the most commercially promising oncology drugs of the decade. The acquisition was Pfizer's first major commitment to oncology as a primary strategic growth focus rather than a secondary therapeutic area, signaling a deliberate shift toward cancer treatment as an organizational priority.
Seagen Inc.2023$43.0BPfizer acquired Seagen for approximately $43 billion in December 2023 to secure leadership in antibody-drug conjugate technology, the fastest-growing drug modality in oncology. Seagen's four commercially approved ADC productsAdcetris, Padcev, Tivdak, and Tukysaprovided immediate revenue contribution while the ADC platform technology provided the foundation for Pfizer's oncology pipeline strategy through 2030. The acquisition represented Pfizer's response to the anticipated loss of exclusivity on Ibrance and the broader need to establish a new oncology platform capable of generating multi-billion-dollar revenues independent of CDK4/6 inhibitor franchise sustainability.
Metsera, Inc.2025$7.0BRe-enter the obesity market after Pfizer discontinued its in-house oral GLP-1 candidates danuglipron and lotiglipron. Metsera brought injectable and oral incretin and amylin candidates, including monthly-dosing programs.
What companies has Pfizer bought?
Major acquisitions by Pfizer documented here include Warner-Lambert Company (2000), Wyeth (2009), Pharmacia Corporation (2003), Seagen Inc. (2023) and Medivation Inc. (2016).
What is Pfizer's most recent acquisition?
The most recent Pfizer acquisition documented here is Metsera, Inc., in 2025, for $7B.

Metsera, Inc.

2025

$7.0B

Why

Re-enter the obesity market after Pfizer discontinued its in-house oral GLP-1 candidates danuglipron and lotiglipron. Metsera brought injectable and oral incretin and amylin candidates, including monthly-dosing programs.

Impact

Pfizer paid $65.60 per share in cash (about $7.0 billion enterprise value) plus a contingent value right of up to $20.65 per share, valuing the deal at up to about $10 billion after a bidding contest with Novo Nordisk. The deal closed in November 2025.

Outcome

Early: results depend on Phase 2 and Phase 3 obesity data against Eli Lilly and Novo Nordisk incumbents.

Source →

Seagen Inc.

2023

$43.0B

Why

Pfizer acquired Seagen for approximately $43 billion in December 2023 to secure leadership in antibody-drug conjugate technology, the fastest-growing drug modality in oncology. Seagen's four commercially approved ADC productsAdcetris, Padcev, Tivdak, and Tukysaprovided immediate revenue contribution while the ADC platform technology provided the foundation for Pfizer's oncology pipeline strategy through 2030. The acquisition represented Pfizer's response to the anticipated loss of exclusivity on Ibrance and the broader need to establish a new oncology platform capable of generating multi-billion-dollar revenues independent of CDK4/6 inhibitor franchise sustainability.

Impact

Seagen added four marketed ADCs (Adcetris, Padcev, Tivdak and Tukysa) and an ADC pipeline. Padcev, combined with Keytruda in first-line bladder cancer, became the fastest-growing contributor.

Outcome

The financial outcome will be clearer later in the decade as pipeline readouts arrive. Pfizer funded the deal largely with about $31 billion of new bonds issued in 2023, which increased interest expense and prioritized debt reduction.

Source →

Medivation Inc.

2016

$14.0B

Why

Pfizer acquired Medivation for $14 billion in 2016 to secure Xtandi (enzalutamide), an androgen receptor inhibitor for prostate cancer that was among the most commercially promising oncology drugs of the decade. The acquisition was Pfizer's first major commitment to oncology as a primary strategic growth focus rather than a secondary therapeutic area, signaling a deliberate shift toward cancer treatment as an organizational priority.

Impact

Xtandi, co-commercialized with Astellas, has generated billions of dollars in annual alliance revenue and received label expansions into earlier stages of prostate cancer. The deal also built oncology commercial capabilities that Pfizer later used for Seagen.

Outcome

Generally viewed as a successful deal thanks to Xtandi's durable growth, though the drug faces loss of exclusivity in the late 2020s.

Source →

Wyeth

2009

$68.0B

Why

Pfizer acquired Wyeth for $68 billion during the financial crisis of 2009, using the depressed asset valuations of the period to complete what was then one of the largest pharmaceutical acquisitions in history. The primary strategic targets were the Prevnar pneumococcal vaccine franchise, the Enbrel (etanercept) biologics franchise for rheumatoid arthritis and other inflammatory conditions, the Effexor and Pristiq antidepressants, and Wyeth's substantial consumer healthcare business.

Impact

Wyeth gave Pfizer large-molecule biologics and vaccine capabilities it had lacked. The Prevnar franchise, which moved from Prevnar 7 to Prevnar 13 and Prevnar 20, generated about $6.4 billion in 2024 and remains one of Pfizer's largest product lines. Enbrel added international revenue for years despite biosimilar competition.

Outcome

The Wyeth acquisition has generated substantial long-term value for Pfizer shareholders through the Prevnar vaccine franchise, which has proven durable through product evolution and global market expansion. The acquisition also established Pfizer's willingness to pursue transformational deals during periods of financial market stressa capital allocation instinct that informed the Seagen acquisition strategy during the 2023 biotech valuation correction.

Source →

Pharmacia Corporation

2003

$60.0B

Why

Pfizer acquired Pharmacia Corporation for approximately $60 billion in 2003 to add the Celebrex (celecoxib) COX-2 inhibitor franchise, the cancer drug Camptosar, ophthalmology products, and a substantial pipeline. The acquisition was also motivated by post-Lipitor diversification concerns and the need to add research capabilities and marketed products to offset anticipated future patent expirations across the combined portfolio.

Impact

The Pharmacia acquisition significantly expanded Pfizer's cancer treatment portfolio and added the Depo-Provera contraceptive franchise. Celebrex became a durable multi-billion-dollar revenue contributor for Pfizer despite the COX-2 class controversy that followed the withdrawal of Merck's Vioxx in 2004. The acquisition also brought Pfizer the animal health assets that would eventually be spun off as Zoetis in 2013.

Outcome

The Pharmacia deal is generally viewed as a mixed result. Celebrex became a multi-billion-dollar product until US generic entry in late 2014, but the 2009 Department of Justice settlement over off-label marketing of Bextra and other drugs cost Pfizer $2.3 billion. Pharmacia-era animal health assets later became part of Zoetis, which Pfizer separated in 2013.

Source →

Warner-Lambert Company

2000

$111.0B

Why

Pfizer pursued Warner-Lambert to acquire the Lipitor (atorvastatin) cholesterol-lowering statin franchise which was already on track to become the best-selling drug in history at the time of the acquisition. The deal was structured as a hostile takeover after Warner-Lambert had announced a competing merger agreement with American Home Products (later Wyeth), and Pfizer outbid with a $111 billion all-stock offer. The acquisition also brought significant consumer healthcare brands including Listerine, Benadryl, and Halls.

Impact

Lipitor under Pfizer's commercial stewardship generated cumulative global sales of more than US$125 billion, making it the world's top-selling drug for years; AbbVie's Humira later took that crown, with about US$200 billion in sales over two decades. The Warner-Lambert deal more than doubled Pfizer's revenue scale and established it as the world's largest pharmaceutical company by revenues. The consumer healthcare brands later became the basis of a spin-off strategy, while the pharmaceutical assetsparticularly the Parke-Davis legacy pipelineprovided a decade of commercial productivity.

Outcome

The acquisition achieved its primary strategic objective of securing the Lipitor franchise, which generated peak annual revenues of approximately $13 billion in 2006. However, Lipitor's patent expiration in 2011 and subsequent generic competition eroded revenues to approximately $2 billion by 2013, validating critics' concerns that the deal created an overly concentrated revenue dependency. The consumer healthcare business was eventually spun off and contributed to the formation of Haleon plc. The Warner-Lambert deal is studied extensively in business schools as a case study in both hostile takeover tactics and the risks of acquisition-driven pharmaceutical growth strategies.

Source →

Pfizer Inc.'s Growth & Acquisition Strategy

Pfizer's growth plan has three parts. Oncology: the $43 billion Seagen deal (closed December 2023) added Padcev, Adcetris, Tukysa and Tivdak, and Pfizer licensed 3SBio's PD-1xVEGF bispecific in 2025 and signed a 12-program cancer collaboration with Innovent Biologics in May 2026 ($650 million upfront, up to $10.5 billion total). Obesity: Pfizer acquired Metsera in November 2025 for about $10 billion including contingent value rights, after a bidding contest with Novo Nordisk. Cost: a multi-year cost realignment and manufacturing optimization program funds R&D and protects margins.

How Pfizer Inc. Makes Money

Pfizer makes money by selling patented prescription medicines and vaccines to wholesalers, hospitals, governments and pharmacies, with the United States as its largest market. Revenue is concentrated in large franchises such as Eliquis (co-commercialized with Bristol Myers Squibb), the Prevnar pneumococcal vaccines, the Vyndaqel tafamidis family, Ibrance, Xtandi and the Seagen antibody-drug conjugates. Pfizer funds internal R&D but sources much of its pipeline externally through acquisitions (Seagen, Metsera) and licensing deals (Innovent, 3SBio), then uses its regulatory, manufacturing and commercial scale to launch products globally during their exclusivity window.

Pfizer Acquisitions FAQ

What was Pfizer's $43 billion acquisition of Seagen in 2023?

In December 2023, Pfizer completed its $43 billion acquisition of Seagen Inc. for $229 per share in cash. The mega-acquisition brought world-leading Antibody-Drug Conjugate (ADC) technology and four commercial blockbuster cancer medicines (Padcev, Adcetris, Tukysa, Tivdak) into Pfizer Oncology.

What was the landmark $11.6 billion acquisition of Biohaven Pharmaceuticals in 2022?

In October 2022, Pfizer acquired Biohaven Pharmaceuticals for $11.6 billion in cash, securing the major oral CGRP migraine blockbuster Nurtec ODT (rimegepant) and expanding Pfizer's specialty primary care portfolio.

What was the acquisition of Arena Pharmaceuticals in 2022?

In March 2022, Pfizer acquired Arena Pharmaceuticals for $6.7 billion in cash, adding Velsipity (etrasimod), an oral S1P receptor modulator for the treatment of moderate-to-severe active ulcerative colitis.

What was the acquisition of Global Blood Therapeutics (GBT) in 2022?

In October 2022, Pfizer acquired Global Blood Therapeutics for $5.4 billion in cash, adding Oxbryta (voxelotor) and next-generation pipeline therapies for the treatment of Sickle Cell Disease.

What was the historic $90 billion acquisition of Warner-Lambert in 2000?

In 2000, Pfizer completed the largest hostile takeover in pharmaceutical history by acquiring Warner-Lambert for $90 billion, securing full proprietary rights to Lipitor, which went on to generate over $130 billion in cumulative lifetime sales.

What was the $68 billion acquisition of Wyeth in 2009?

In 2009, Pfizer acquired Wyeth for $68 billion, transforming Pfizer from a pure small-molecule chemical drug maker into a biologics and vaccine leader by acquiring the multi-billion-dollar Prevnar pneumococcal vaccine and Enbrel.

What was the historic spinoff and merger creating Viatris in 2020?

In November 2020, Pfizer spun off its Upjohn established generic medicines division (Lipitor, Norvasc, Celebrex, Viagra) and merged it with Mylan N.V. to create Viatris Inc., allowing Pfizer to focus 100% on high-margin, innovative biopharmaceutical R&D.

What was the acquisition of Array BioPharma in 2019?

In July 2019, Pfizer acquired Array BioPharma for $11.4 billion, securing targeted colorectal cancer combination therapies Braftovi (encorafenib) and Mektovi (binimetinib) and expanding Pfizer's precision oncology pipeline.

Related Companies

Novo Nordisk A/SEli Lilly and CompanyNovartis AGBausch Health Companies Inc.

Compare Pfizer Inc. With Competitors

Pfizer Inc. vs Novo Nordisk A/SPfizer Inc. vs Eli Lilly and CompanyPfizer Inc. vs Novartis AGPfizer Inc. vs Bausch Health Companies Inc.

Related M&A Histories

Compare corporate acquisition records, deal values, and strategic targets

Competitor

Novo Nordisk A/S

View M&A Histories
Competitor

Eli Lilly and Company

View M&A Histories
Competitor

Novartis AG

View M&A Histories
Competitor

Bausch Health Companies Inc.

View M&A Histories
Competitor

Johnson And Johnson

View M&A Histories
Competitor

Merck

View M&A Histories

Explore Pfizer

Core profile pages, founders and related research hubs for this company.

Content is for informational purposes only. Not financial advice. Data sourced from SEC filings, annual reports, and public records. See our full disclaimer and methodology.